Molecular Mechanisms of Castrate-Resistant Prostate Cancer
Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in CRPC have been identified. This focus on understanding the molecular basis of therapeutic resistance, including lineage plasticity, neuroendocrine transformation, and a range of other implicated genomic alterations will hopefully inform decision-making in the care of this lethal cancer.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Srinath Kotamarti, Andrew J. Armstrong, Thomas J. Polascik, Judd W. Moul Source Type: research